Youcare Pharmaceutical Group Co. Ltd. A

Youcare Pharmaceutical announced that its subsidiary Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. recently received a letter from the US FDA agreeing to the clinical trial application for YKYY033 injection for the prevention and treatment of arterial and venous thrombosis. YKYY033 is a double-stranded siRNA drug conjugated with a GalNAc ligand that silences the mRNA transcribed from the coagulation factor XI gene through RNA interference, inhibiting the production of FXI protein. Preclinical studies have shown good safety and tolerability, and it has demonstrated significant antithrombotic efficacy in multiple animal models without increasing bleeding risk. The product received clinical trial approval from the NMPA for multiple anticoagulation-related indications in June and July 2026, and Phase I clinical trials are progressing steadily.

Youcare Pharmaceutical announced that its YKYY017 inhalation aerosol has received clinical trial approval from the National Medical Products Administration for a new indication, intended for the treatment and prevention of human coronavirus OC43-related respiratory infections. The drug is a lipopeptide compound jointly developed by the company and the Institute of Pathogen Biology at the Chinese Academy of Medical Sciences. It belongs to the latest generation of coronavirus membrane fusion inhibitors, blocking virus-host cell fusion by competitively binding to the HR1 region of the S2 subunit of the coronavirus spike protein. It exhibits broad-spectrum inhibitory activity against multiple coronaviruses, including SARS-CoV-2 and HCoV-OC43.